FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.22-SNAPSHOT  |  FHIR Version n/a  User: [n/a]

781125008: Fremanezumab (substance)

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2019. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
3744983010 Fremanezumab (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
3744984016 Fremanezumab en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core
5587181000241113 fremanezumab fr Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Fremanezumab (substance) This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context. Calcitonin gene-related peptide receptor antagonist (disposition) true Inferred relationship Some
Fremanezumab (substance) Is a Monoclonal antibody true Inferred relationship Some
Fremanezumab (substance) Is a Substance with calcitonin gene-related peptide receptor antagonist mechanism of action (substance) true Inferred relationship Some
Inbound Relationships Type Active Source Characteristic Refinability Group
Fremanezumab-containing product The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Fremanezumab (substance) Inferred relationship Some 1
Fremanezumab only product The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Fremanezumab (substance) Inferred relationship Some 1
Product containing only fremanezumab in parenteral dose form (medicinal product form) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Fremanezumab (substance) Inferred relationship Some 1
Fremanezumab-containing product in parenteral dose form The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Fremanezumab (substance) Inferred relationship Some 1
Product containing precisely fremanezumab 150 milligram/1 milliliter conventional release solution for injection (clinical drug) The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Fremanezumab (substance) Inferred relationship Some 1
Product containing precisely fremanezumab 150 milligram/1 milliliter conventional release solution for injection (clinical drug) This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. True Fremanezumab (substance) Inferred relationship Some 1

This concept is not in any reference sets

Back to Start